GlaxoSmithKline Pakistan Limited
Public pharmaceutical company - GSK group · Karachi · Pakistan
Pakistan operating company of the GSK group, supplying and supporting prescription medicines and healthcare products in the local market.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public pharmaceutical company - GSK group
- Address
- 35 Dockyard Road, West Wharf, Karachi 74000, Pakistan · 74000
- Website
- pk.gsk.com ↗
- Phone
- +92 21 111 475 725
- pk.medinfo@gsk.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Engerix-B | Hepatitis B vaccine (recombinant HBsAg) | 20 mcg/dose | Suspension for injection | 1 PFS | 009823 | PKR 1,603.19 | PKR 1,603.19/vial/unit | 90% above median |
| Engerix-B | Hepatitis B vaccine (recombinant HBsAg) | 10 mcg/dose | Suspension for injection | 1 PFS | 012370 | PKR 1,068.80 | PKR 1,068.80/vial/unit | No comparator |
| Engerix-B | Hepatitis B vaccine (recombinant HBsAg) | 10 mcg/0.5 mL | Injection | 1 Vial | 012370 | PKR 511.61 | PKR 511.61/vial/unit | No comparator |
| Fefol Spansule | Iron + Folic acid | 250 mg + 0.5 mg | Capsule | 56's | 000401 | PKR 264.28 | PKR 4.72/capsule | Near median |
| Fefol Spansule | Iron + Folic acid | 250 mg + 0.5 mg | Capsule | 30's | 000401 | PKR 148.47 | PKR 4.95/capsule | Near median |
| FixVal Oral | Cefixime | 100 mg/5 mL | Oral suspension | 90ml | 067068 | PKR 862.08 | PKR 9.58/mL | 8% below median |
| FixVal Oral | Cefixime | 100 mg/5 mL | Oral suspension | 30ml | 067068 | PKR 312.22 | PKR 10.41/mL | Near median |
| FixVal Oral | Cefixime | 100 mg/5 mL | Oral suspension | 60ml | 067068 | PKR 593.20 | PKR 9.89/mL | 5% below median |
| Fortum | Ceftazidime | 1 g | Injection | 1's | 010077 | PKR 923.02 | PKR 923.02/vial/unit | 102% above median |
| Fortum | Ceftazidime | 500 mg | Injection | 1's | 010078 | PKR 553.58 | PKR 553.58/vial/unit | 128% above median |
| Fortum | Ceftazidime | 250 mg | Injection | 1's | 015819 | PKR 286.05 | PKR 286.05/vial/unit | 79% above median |
| Havrix 1440 | Hepatitis A vaccine, inactivated | 1440 ELISA units/1 mL dose | Suspension for IM injection (vaccine) | 1's | 031382 | PKR 4,543.76 | PKR 4,543.76/vial/unit | No comparator |
| Havrix 720 Junior | Hepatitis A vaccine | 720 ELISA units/0.5 mL | Vaccine | mono dose | 027318 | PKR 2,788.23 | — | No comparator |
| Infanrix Hexa Combined Diphtheria -Tetanus-Acellular Pertussis, Hepatitis B, enhanced Inactivated Polio Vaccine and Haemophilus Influenza Type b (Hib) VaccineSource observed | — | — | Vaccine | mono dose | 028422Official source ↗ | No indexed price | — | — |
| Keppra | Levetiracetam | 250 mg | Tablet | 30's | 045684 | PKR 2,589.22 | PKR 86.31/tablet | 56% above median |
| Keppra | Levetiracetam | 250 mg | Tablet | 1's | 045684 | PKR 86.31 | PKR 86.31/tablet | 56% above median |
| Keppra | Levetiracetam | 500 mg | Tablet | 30's | 045685 | PKR 4,290.72 | PKR 143.02/tablet | 51% above median |
| Keppra | Levetiracetam | 500 mg | Tablet | 1's | 045685 | PKR 143.02 | PKR 143.02/tablet | 51% above median |
| Lamictal | Lamotrigine = | 25 mg | Tablet | 30's | 014918 | PKR 1,488.67 | PKR 49.62/tablet | 141% above median |
| Lamictal | Lamotrigine = | 50 mg | Tablet | 30's | 014919 | PKR 2,483.97 | PKR 82.80/tablet | 201% above median |
| Lamictal | Lamotrigine = | 100 mg | Tablet | 30's | 014921 | PKR 4,220.75 | PKR 140.69/tablet | 310% above median |
| Lamictal | Lamotrigine = | 5 mg | Tablet | 30's | 019532 | PKR 828.17 | PKR 27.61/tablet | 752% above median |
| Lamictal | Lamotrigine = | 2 mg | Tablet | 30's | 039900 | PKR 507.67 | PKR 16.92/tablet | No comparator |
| Lanoxin | Digoxin | 0.25 mg | Tablet | 50's | 000364 | PKR 179.14 | PKR 3.58/tablet | Near median |
| Lanoxin | Digoxin | 0.25 mg | Tablet | 100's | 000364 | PKR 344.94 | PKR 3.45/tablet | Near median |
| Lanoxin | Digoxin | 0.25 mg | Tablet | 25's | 000364 | PKR 96.37 | PKR 3.85/tablet | 12% above median |
| Lanoxin | Digoxin | 0.5 mg/2 mL | Injection | 5's | 089276 | PKR 125.84 | PKR 25.17/vial/unit | No comparator |
| Lotrix | Permethrin | 5% | Cream | 30g | 010516 | PKR 126.02 | PKR 4.20/g | 8% above median |
| Maxolon | Metoclopramide | 10 mg | Tablet | 200's | 000177 | PKR 504.34 | PKR 2.52/tablet | 19% above median |
| Maxolon | Metoclopramide | 10 mg | Tablet | 100's | 000177 | PKR 267.40 | PKR 2.67/tablet | 26% above median |
| Maxolon | Metoclopramide | 10 mg/2 mL | Injection | 10's | 089275 | PKR 413.07 | PKR 41.31/vial/unit | Near median |
| Menveo | Meningococcal conjugate vaccine (A, C, Y, W-135) | A 10 mcg + C 5 mcg + W-135 5 mcg + Y 5 mcg / 0.5 mL dose | Powder and solution for injection | 1's | 063927 | PKR 5,488.95 | PKR 5,488.95/vial/unit | No comparator |
| Priorix Tetra Live attenuated Measles Virus (Schwarz Strain) CCID 50, Live attenuated Mumps Virus CCID50, Live attenuated Rubella Virus CCID 50, Live attenuated Varicella Virus (OKA Strain)Source observed | — | — | — | mono dose | 066128Official source ↗ | No indexed price | — | — |
| Priorix Vaccine Live attenuated Measles Virus (Schwarz Strain) CCID 50, Live attenuated Mumps Virus CCID50, Live attenuated Rubella Virus CCID 50Source observed | — | — | Vaccine | mono dose | 027330Official source ↗ | No indexed price | — | — |
| Rotarix | Human rotavirus RIX4414 strain (live, attenuated) | ≥10^6.0 CCID50/dose (1.5 mL) | Oral suspension vaccine | 1dose | 066195 | PKR 5,989.50 | PKR 5,989.50/dose | No comparator |
| Septran | Sulfamethoxazole + Trimethoprim | 80 mg + 400 mg | Tablet | 200's | 000388 | PKR 787.39 | PKR 3.94/tablet | 11% above median |
| Septran DS | Sulfamethoxazole + Trimethoprim | 800 mg + 160 mg | Tablet | 100's | 004926 | PKR 969.34 | PKR 9.69/tablet | Near median |
| Septran Paediatric | Sulfamethoxazole + Trimethoprim | 200 mg + 40 mg / 5 mL | Suspension | 50ml | 000384 | PKR 72.26 | PKR 1.45/mL | 112% above median |
| Septran Paediatric | Sulfamethoxazole + Trimethoprim | 200 mg + 40 mg / 5 mL | Suspension | 100ml | 000384 | PKR 85.10 | PKR 0.85/mL | 25% above median |
| Silvate Silver | Sulphadiazine | 1 % | Cream | 500g | 022433 | PKR 1,341.21 | PKR 2.68/g | 33% below median |
| Stiemazol | Clotrimazole | 1 % | Cream | 10g | 018239 | PKR 133.47 | PKR 13.35/g | 116% above median |
| Stiemazol | Clotrimazole | 1 % | Cream | 60ml | 024757 | PKR 247.56 | PKR 4.13/mL | No comparator |
| Synflorix | Pneumococcal conjugate vaccine (10-valent) | 1 mcg each (1,5,6B,7F,9V,14,23F) + 3 mcg each (4,18C,19F) | Prefilled syringe vaccine injection | 1's | 066129 | PKR 7,363.40 | PKR 7,363.40/syringe | No comparator |
| Thyroxine | Levothyroxine sodium | 50 mcg | Tablet | 100's | 000374 | PKR 267.40 | PKR 2.67/tablet | Near median |
| Tivicay | Dolutegravir | 50 mg | Tablet | 30's | 090532 | PKR 57,906.24 | PKR 1,930.21/tablet | 396% above median |
| Traxon | Ceftriaxone | 1 g | Injection | 1's | 017889 | PKR 531.19 | PKR 531.19/vial/unit | 12% below median |
| Traxon | Ceftriaxone | 250 mg | Injection | 1's | 017891 | PKR 194.77 | PKR 194.77/vial/unit | Near median |
| Traxon | Ceftriaxone | 250 mg | IM injection | 1's | 089165 | PKR 175.19 | PKR 175.19/vial/unit | 11% below median |
| Traxon | Ceftriaxone | 1 g | Injection | 1's | 089166 | PKR 556.80 | PKR 556.80/vial/unit | 8% below median |
| Varilrix vaccine Live attenuated Varicella Zoster virus (OKA StrainSource observed | — | — | Vaccine | mono dose | 028421Official source ↗ | No indexed price | — | — |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.